Article Sidebar
Published:
Nov 19, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparative efficacy and clinical outcomes of compound betamethasone and triamcinolone acetonide on IL-6 and IL-17 in keloid treatment.
Abstract
Purpose: To determine the efficacy and clinical outcomes of compound betamethasone and triamcinolone acetonide on interleukin-6 (IL-6) and interleukin-17 (IL-17) in keloid management. Methods: This study was a retrospective analysis of 118 keloid patients treated at The First Affiliated Hospital of Hebei North University, Zhangjiakou, China from January 2020 to December 2022. Patients were randomly divided into Group A (comprising 62 patients who received compound betamethasone) and Group B (comprising 56 patients who received triamcinolone acetonide). Treatment efficacy after 6 months using the Vancouver Scar Scale (VSS), changes in IL-6 and IL-17 levels, and incidence of treatment-related adverse reactions were compared in both groups. Results: Group A demonstrated significantly higher overall response rate compared to Group B (p < 0.05). Both groups showed significant reductions in IL-6 and IL-17 levels after treatment (p < 0.05). However, Group A showed significantly lower IL-6 and IL-17 (p < 0.05) and significantly higher VSS scores t Group B (p < 0.05). Incidence of adverse reactions was comparable between the groups (p > 0.05). Conclusion: Compound betamethasone shows superior efficacy in reducing IL-6 and IL-17 levels and improves scar appearance in keloid patients comparable to triamcinolone acetonide. Prospective studies with larger sample sizes to evaluate the efficacy of various treatments or combination therapies should be conducted.
